FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

ConditionsFOXP1 Mental Retardation With Language Impairment and With or Without Autistic Features Autism Spectrum Disorder

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age2+

SponsorIcahn School of Medicine at Mount Sinai

About this trial

FOXP1, also known as Forkhead-box Protein P1, is a transcription factor protein belonging to the FOX gene family. Disruptions in the FOXP1 gene cause a phenotype characterized by global developmental delay, speech deficits, mild dysmorphic features, and traits of autism spectrum disorder. This study seeks to characterize FOXP1-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.

Eligibility criteria

Qualifiers

Eligible participants must have a documented variant affecting the FOXP1 gene that the research team determines to be likely or definitely pathogenic.

Eligible participants must be at least 2 years of age.

Disqualifiers

none

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Icahn School of Medicine at Mount Sinai

Lead sponsor

The Seaver Foundation

Collaborator

Autism Science Foundation

Collaborator

Research Foundation for Mental Hygiene, Inc.

Collaborator

Source ClinicalTrials.gov